The DOI matches its Crossref record; 51 of the 51 references it cites were found in a registry or an index.
Exploring the specificity of the PI3K family inhibitor LY294002
Open accessAbstract
The PI3Ks (phosphatidylinositol 3-kinases) regulate cellular signalling networks that are involved in processes linked to the survival, growth, proliferation, metabolism and specialized differentiated functions of cells. The subversion of this network is common in cancer and has also been linked to disorders of inflammation. The elucidation of the physiological function of PI3K has come from pharmacological studies, which use the enzyme inhibitors Wortmannin and LY294002, and from PI3K genetic knockout models of the effects of loss of PI3K function. Several reports have shown that LY294002 is not exclusively selective for the PI3Ks, and could in fact act on other lipid kinases and additional apparently unrelated proteins. Since this inhibitor still remains a drug of choice in numerous PI3K studies (over 500 in the last year), it is important to establish the precise specificity of this compound. We report here the use of a chemical proteomic strategy in which an analogue of LY294002, PI828, was immobilized onto epoxy-activated Sepharose beads. This affinity material was then used as a bait to fish-out potential protein targets from cellular extracts. Proteins with high affinity for immobilized PI828 were separated by one-dimensional gel electrophoresis and identified by liquid chromatography–tandem MS. The present study reveals that LY294002 not only binds to class I PI3Ks and other PI3K-related kinases, but also to novel targets seemingly unrelated to the PI3K family.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Inhibition of glycogen synthase kinase-3 by insulin mediated by protein kinase B
Cross, D. A. E., Alessi, D. R., Cohen, P., Andjelkovich, M., & Hemmings, B. A. (1995) · Nature · doi:10.1038/378785a0 · Cited by 5,244
High Frequency of Mutations of the PIK3CA Gene in Human Cancers
Samuels, Y., Wang, Z., Bardelli, A., Silliman, N., Ptak, J., Szabo, S., Yan, H., Gazdar, A., Powell, S. M., Riggins, G. J., et al. (2004) · Science · doi:10.1126/science.1096502 · Cited by 3,437
The evolution of phosphatidylinositol 3-kinases as regulators of growth and metabolism
Engelman, J. A., Luo, J., & Cantley, L. C. (2006) · Nature Reviews Genetics · doi:10.1038/nrg1879 · Cited by 3,330
Vlahos, C. J., Matter, W. F., Hui, K. Y., & Brown, R. F. (1994) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(17)37680-9 · Cited by 3,240
Specificity and mechanism of action of some commonly used protein kinase inhibitors
DAVIES, S. P., REDDY, H., CAIVANO, M., & COHEN, P. (2000) · Biochemical Journal · doi:10.1042/bj3510095 · Cited by 3,132
Exploiting the PI3K/AKT Pathway for Cancer Drug Discovery
Hennessy, B. T., Smith, D. L., Ram, P. T., Lu, Y., & Mills, G. B. (2005) · Nature Reviews Drug Discovery · doi:10.1038/nrd1902 · Cited by 2,185
GSK-3: tricks of the trade for a multi-tasking kinase
Doble, B. W., & Woodgett, J. R. (2003) · Journal of Cell Science · doi:10.1242/jcs.00384 · Cited by 2,084
Assembly of Cell Regulatory Systems Through Protein Interaction Domains
Pawson, T., & Nash, P. (2003) · Science · doi:10.1126/science.1083653 · Cited by 1,422
Beyond PTEN mutations: the PI3K pathway as an integrator of multiple inputs during tumorigenesis
Cully, M., You, H., Levine, A. J., & Mak, T. W. (2006) · Nature Reviews Cancer · doi:10.1038/nrc1819 · Cited by 1,233
Walker, E. H., Pacold, M. E., Perisic, O., Stephens, L., Hawkins, P. T., Wymann, M. P., & Williams, R. L. (2000) · Molecular Cell · doi:10.1016/s1097-2765(05)00089-4 · Cited by 1,197
A Pharmacological Map of the PI3-K Family Defines a Role for p110α in Insulin Signaling
Knight, Z. A., Gonzalez, B., Feldman, M. E., Zunder, E. R., Goldenberg, D. D., Williams, O., Loewith, R., Stokoe, D., Balla, A., Toth, B., et al. (2006) · Cell · doi:10.1016/j.cell.2006.03.035 · Cited by 1,174
Arcaro, A., & Wymann, M. P. (1993) · Biochemical Journal · doi:10.1042/bj2960297 · Cited by 1,140
The Role of Phosphoinositide 3-Kinase Lipid Products in Cell Function
Rameh, L. E., & Cantley, L. C. (1999) · Journal of Biological Chemistry · doi:10.1074/jbc.274.13.8347 · Cited by 987
Impaired B and T Cell Antigen Receptor Signaling in p110δ PI 3-Kinase Mutant Mice
Okkenhaug, K., Bilancio, A., Farjot, G., Priddle, H., Sancho, S., Peskett, E., Pearce, W., Meek, S. E., Salpekar, A., Waterfield, M. D., et al. (2002) · Science · doi:10.1126/science.1073560 · Cited by 946
Self-citationSignaling by Distinct Classes of Phosphoinositide 3-Kinases
Vanhaesebroeck, B., & Waterfield, M. D. (1999) · Experimental Cell Research · doi:10.1006/excr.1999.4701 · Cited by 853
Self-citationPhosphatidylinositol 3-kinase mutations identified in human cancer are oncogenic
Kang, S., Bader, A. G., & Vogt, P. K. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0408864102 · Cited by 823
Beclin–phosphatidylinositol 3‐kinase complex functions at the trans‐Golgi network
Kihara, A., Kabeya, Y., Ohsumi, Y., & Yoshimori, T. (2001) · The EMBO Reports · doi:10.1093/embo-reports/kve061 · Cited by 813
Yano, H., Nakanishi, S., Kimura, K., Hanai, N., Saitoh, Y., Fukui, Y., Nonomura, Y., & Matsuda, Y. (1993) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(19)74466-4 · Cited by 725
Brunn, G. J., Williams, J., Sabers, C., Wiederrecht, G., Lawrence, J. C., & Abraham, R. T. (1996) · The EMBO Journal · doi:10.1002/j.1460-2075.1996.tb00911.x · Cited by 723
The double bromodomain protein Brd4 binds to acetylated chromatin during interphase and mitosis
Dey, A., Chitsaz, F., Abbasi, A., Misteli, T., & Ozato, K. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1433065100 · Cited by 669
Function of the p97–Ufd1–Npl4 complex in retrotranslocation from the ER to the cytosol
Ye, Y., Meyer, H. H., & Rapoport, T. A. (2003) · The Journal of Cell Biology · doi:10.1083/jcb.200302169 · Cited by 596
A dual PI3 kinase/mTOR inhibitor reveals emergent efficacy in glioma
Fan, Q.-W., Knight, Z. A., Goldenberg, D. D., Yu, W., Mostov, K. E., Stokoe, D., Shokat, K. M., & Weiss, W. A. (2006) · Cancer Cell · doi:10.1016/j.ccr.2006.03.029 · Cited by 585
Carpenter, C. L., & Cantley, L. C. (1996) · Current Opinion in Cell Biology · doi:10.1016/s0955-0674(96)80060-3 · Cited by 534
Structural insights into phosphoinositide 3-kinase catalysis and signalling
Walker, E. H., Perisic, O., Ried, C., Stephens, L., & Williams, R. L. (1999) · Nature · doi:10.1038/46319 · Cited by 494
Critical role for the p110α phosphoinositide-3-OH kinase in growth and metabolic regulation
Foukas, L. C., Claret, M., Pearce, W., Okkenhaug, K., Meek, S., Peskett, E., Sancho, S., Smith, A. J. H., Withers, D. J., & Vanhaesebroeck, B. (2006) · Nature · doi:10.1038/nature04694 · Cited by 463
Meyer, H. H., Shorter, J. G., Seemann, J., Pappin, D., & Warren, G. (2000) · The EMBO Journal · doi:10.1093/emboj/19.10.2181 · Cited by 445
Roscovitine Targets, Protein Kinases and Pyridoxal Kinase
Bach, S., Knockaert, M., Reinhardt, J., Lozach, O., Schmitt, S., Baratte, B., Koken, M., Coburn, S. P., Tang, L., Jiang, T., et al. (2005) · Journal of Biological Chemistry · doi:10.1074/jbc.m500806200 · Cited by 356
An efficient proteomics method to identify the cellular targets of protein kinase inhibitors
Godl, K., Wissing, J., Kurtenbach, A., Habenberger, P., Blencke, S., Gutbrod, H., Salassidis, K., Stein-Gerlach, M., Missio, A., Cotten, M., et al. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2535024100 · Cited by 336
Protein kinase CK2 in mammary gland tumorigenesis
Landesman-Bollag, E., Romieu-Mourez, R., Song, D. H., Sonenshein, G. E., Cardiff, R. D., & Seldin, D. C. (2001) · Oncogene · doi:10.1038/sj.onc.1204411 · Cited by 289
Gharbi, S., Gaffney, P., Yang, A., Zvelebil, M. J., Cramer, R., Waterfield, M. D., & Timms, J. F. (2002) · Molecular & Cellular Proteomics · doi:10.1074/mcp.t100007-mcp200 · Cited by 283
Self-citationBilancio, A., Okkenhaug, K., Camps, M., Emery, J. L., Ruckle, T., Rommel, C., & Vanhaesebroeck, B. (2006) · Blood · doi:10.1182/blood-2005-07-3041 · Cited by 212
Pim-1 Ligand-bound Structures Reveal the Mechanism of Serine/Threonine Kinase Inhibition by LY294002
Jacobs, M. D., Black, J., Futer, O., Swenson, L., Hare, B., Fleming, M., & Saxena, K. (2005) · Journal of Biological Chemistry · doi:10.1074/jbc.m413155200 · Cited by 192
Cloning and Characterization of a Wortmannin-sensitive Human Phosphatidylinositol 4-Kinase
Meyers, R., & Cantley, L. C. (1997) · Journal of Biological Chemistry · doi:10.1074/jbc.272.7.4384 · Cited by 172
Intracellular Targets of Paullones
Knockaert, M., Wieking, K., Schmitt, S., Leost, M., Grant, K. M., Mottram, J. C., Kunick, C., & Meijer, L. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m202651200 · Cited by 144
p97: The Cell's Molecular Purgatory?
Halawani, D., & Latterich, M. (2006) · Molecular Cell · doi:10.1016/j.molcel.2006.06.003 · Cited by 143
Role of Phosphoinositide 3-Kinase Regulatory Isoforms in Development and Actin Rearrangement
Brachmann, S. M., Yballe, C. M., Innocenti, M., Deane, J. A., Fruman, D. A., Thomas, S. Μ., & Cantley, L. C. (2005) · Molecular and Cellular Biology · doi:10.1128/mcb.25.7.2593-2606.2005 · Cited by 125
Ding, J., Vlahos, C. J., Liu, R., Brown, R. F., & Badweyt, J. A. (1995) · Journal of Biological Chemistry · doi:10.1074/jbc.270.19.11684 · Cited by 123
Downing, G. J., Kim, S. E., Nakanishi, S., Catt, K. J., & Balla, T. (1996) · Biochemistry · doi:10.1021/bi9517493 · Cited by 116
Bromodomain analysis of Brd2-dependent transcriptional activation of cyclin A
Sinha, A., Faller, D. V., & Denis, G. V. (2005) · Biochemical Journal · doi:10.1042/bj20041793 · Cited by 116
Abdul‐Ghani, R., Serra, V., Győrffy, B., Jürchott, K., Solf, A., Dietel, M., & Schäfer, R. (2005) · Oncogene · doi:10.1038/sj.onc.1209201 · Cited by 115
Phosphoinositide 3-kinases as drug targets in cancer
Stephens, L., WILLIAMS, R., & Hawkins, P. T. (2005) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2005.03.002 · Cited by 106
Activation Loop Sequences Confer Substrate Specificity to Phosphoinositide 3-Kinase α (PI3Kα)
Pirola, L., Zvelebil, M., Bulgarelli-Leva, G., OBBERGHEN, E. V., Waterfield, M. D., & Wymann, M. P. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m011330200 · Cited by 94
Self-citationPoh, T. W., & Pervaiz, S. (2005) · Cancer Research · doi:10.1158/0008-5472.can-05-0152 · Cited by 88
Yamaguchi, K., Lee, S., Kim, J., Wimalasena, J., Kitajima, S., & Baek, S. J. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-1987 · Cited by 81
Farina, A., Hattori, M., Qin, J., Nakatani, Y., Minato, N., & Ozato, K. (2004) · Molecular and Cellular Biology · doi:10.1128/mcb.24.20.9059-9069.2004 · Cited by 73
Kim, K. H., Choi, K.-M., PARK, J., & KWON, T. (2005) · Immunology Letters · doi:10.1016/j.imlet.2004.12.007 · Cited by 64
Therapeutic potential of phosphoinositide 3-kinase inhibitors
Drees, B. E., Mills, G. B., Rommel, C., & Prestwich, G. D. (2004) · Expert Opinion on Therapeutic Patents · doi:10.1517/13543776.14.5.703 · Cited by 42
Kang, J. H., Hong, M., Kim, D. W., Park, J., Kang, T., Won, M. H., Baek, N., Moon, B. J., Choi, S. Y., & Kwon, O. (2004) · European Journal of Biochemistry · doi:10.1111/j.1432-1033.2004.04175.x · Cited by 41
Rogers, S. J., Box, C., Harrington, K. J., Nutting, C. M., Rhys‐Evans, P. H., & Eccles, S. A. (2005) · Expert Opinion on Therapeutic Targets · doi:10.1517/14728222.9.4.769 · Cited by 35
PDE2 inhibition by the PI3 kinase inhibitor LY294002 and analogues
Abbott, B. M., & Thompson, P. E. (2004) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2004.03.043 · Cited by 28
Choi, E.-K., Park, H., Ma, J.-S., Lee, H., Kang, H., Kim, B.-G., & Kang, I. (2004) · FEBS Letters · doi:10.1016/s0014-5793(04)00058-4 · Cited by 25
Cited by
The selectivity of protein kinase inhibitors: a further update
Bain, J., Plater, L., Elliott, M., Shpiro, N., Hastie, C. J., Mclauchlan, H., Klevernic, I., Arthur, J. S. C., Alessi, D. R., & Cohen, P. (2007) · Biochemical Journal · doi:10.1042/bj20070797 · Cited by 2,520
PI3K and cancer: lessons, challenges and opportunities
Fruman, D. A., & Rommel, C. (2014) · Nature Reviews Drug Discovery · doi:10.1038/nrd4204 · Cited by 1,709
Active-Site Inhibitors of mTOR Target Rapamycin-Resistant Outputs of mTORC1 and mTORC2
Feldman, M. E., Apsel, B., Uotila, A., Loewith, R., Knight, Z. A., Ruggero, D., & Shokat, K. M. (2009) · PLoS Biology · doi:10.1371/journal.pbio.1000038 · Cited by 1,082
The multifunctional NS1 protein of influenza A viruses
Hale, B. G., Randall, R. E., Ortín, J., & Jackson, D. (2008) · Journal of General Virology · doi:10.1099/vir.0.2008/004606-0 · Cited by 1,079
Targeting phosphoinositide 3-kinase—Moving towards therapy
Marone, R., Cmiljanovic, V., Giese, B., & Wymann, M. P. (2008) · Biochimica et Biophysica Acta (BBA) - Proteins and Proteomics · doi:10.1016/j.bbapap.2007.10.003 · Cited by 548
Metadata
- Authors
- Gharbi, S. I., Zvelebil, M. J., Shuttleworth, S. J., Hancox, T., Saghir, N., Timms, J. F., & Waterfield, M. D.
- Venue
- Biochemical Journal
- Publisher
- Portland Press Ltd.
- Published
- 2007-04-26
- Volume
- 404
- Issue
- 1
- Pages
- 15-21
- ISSN
- 0264-6021 (ISSN-L)
- 1470-8728
- OpenAlex
- W1987642183
- Cited by
- 462
- References
- 51
- FWCI
- 8.98
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.